Skip to main content
Premium Trial:

Request an Annual Quote

Luxia Scientific Inks Microbiome Test Distribution Deal with Life Genomics

NEW YORK (GenomeWeb) – Luxia Scientific announced this week an exclusive distribution agreement with Life Genomics for the commercialization of Luxia's microbiome test in Nordic countries.

Under the terms of the deal, Life Genomics will exclusively distribute Luxia's 1test1 test in Sweden, where the firm is based, as well as in Denmark, Finland, Iceland, and Norway. Additional terms were not disclosed.

The CE-IVD-marked 1test1 analyzes the bacterial content of the gut microbiome. Leveraging 16S rRNA sequencing, it provides information about bacterial diversity and the relative abundance of many bacterial groups that provide beneficial health benefits, Luxia said. According to the company's website, it is collaborating with the Integrated Biobank of Luxembourg to sequence the V3-V4 region of the 16S ribosomal RNA gene.

The 1test1 was launched in France last October and in Luxembourg in November.

Paris-based Luxia launched in June 2018 as a spinoff from the consulting firm of the same name. It was founded by Alessandra Cervino and develops diagnostic tests targeting the microbiome.

Gothenburg-based Life Genomics is a private genetic laboratory founded in 2014 as a spinoff of Tataa Biocenter to develop and offer genetic tests.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.